Zydus Cadila gets DCGI nod for launch of its NCE for diabetes
New Delhi: Cadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes for launch in the country.
Drug Controller General of India (DCGI) has approved Lipaglyn to be used for treating `diabetic dyslipidemeia` for launch, the company said in a filing to BSE.
Commenting on the development Zydus Cadila Chairman and Manging Director Pankaj R Patel said: "Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control."
It has always been our dream to take a molecule right from concept stage to its launch. Today we have realised this dream, he added.
Diabetic dyslipidemeia is a condition where a person is diabetic and has elevated levels of total cholesterol.
Shares of Cadila healthcare were today trading at Rs 780.85 per scrip in the afternoon trade on BSE, down 4.13 per cent from its previous close.
More from India
More from World
More from Sports
More from Entertaiment
- 'Achhe din': Residents of PM Modi's adopted village to get free electricity, work in full swing
- Deepika Padukone, Vin Diesel in first ‘xXx: The Return of Xander Cage’ video – Watch
- Siachen survivor Lance Naik Hanumanthappa brought to Delhi, Army chief Dabir Singh visits RR hospital
- How Lance Naik Hanumanthappa survived 6 days below 25 feet of snow in Siachen
- Siachen miracle: Lance Naik Koppad's wife terms her husband's 'news of being alive' as 'rebirth for family'